Variation assessment for in vitro permeabilities through Yucatan micropig skin

Biological and Pharmaceutical Bulletin

Volumn 34, Issue 4, 2011, Pages 555-561

  Takeuchi, Hiroyuki ^a   Terasaka, Shuichi ^a   Sakurai, Takanobu ^a   Furuya, Atsushi ^a   Urano, Hidetoshi ^a   Sugibayashi, Kenji ^b  

^a TAISHO PHARMACEUTICAL CO LTD   (Japan)

^b JOSAI UNIVERSITY   (Japan)

Author keywords

Human skin; In vitro skin permeability; Inter individual variation; Intra individual variation; Regional variation; Yucatan micropig skin

Indexed keywords

FLURBIPROFEN; ISOSORBIDE DINITRATE; NICORANDIL;

ADULT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG PENETRATION; DRUG STRUCTURE; FEMALE; HUMAN; HUMAN TISSUE; HUMAN VERSUS ANIMAL COMPARISON; IN VITRO STUDY; MALE; MINIPIG; NONHUMAN; SKIN PERMEABILITY; SKINFOLD THICKNESS; SPECIES DIFFERENCE; STRATUM CORNEUM; YUCATAN MICROPIG;

ADMINISTRATION, CUTANEOUS; ANIMALS; BIOLOGICAL TRANSPORT; FLURBIPROFEN; HUMANS; ISOSORBIDE DINITRATE; MODELS, ANIMAL; NICORANDIL; PERMEABILITY; PHARMACOKINETICS; SKIN ABSORPTION; SWINE; SWINE, MINIATURE;

EID: 79953789141     PISSN: 09186158     EISSN: 13475215     Source Type: Journal    
DOI: 10.1248/bpb.34.555     Document Type: Article

References (40)

1. Barbero A. M., Frasch H. F., Toxicol. in Vitro, 23, 1-13 (2009).
2. Bronaugh R. L., Stewart R. F., Congdon E. R., Toxicol. Appl. Pharmacol., 62, 481-488 (1982).
3. EI Maghraby G. M., Barry B. W., Williams A. C., Eur. J. Pharm. Sci., 34, 203-222 (2008).
4. Godin B., Touitou E., Adv. Drug Deliv. Rev., 59, 1152-1161 (2007).
5. Panchagnula R., Stemmer K., Ritschel W. A., Methods Find. Exp. Clin. Pharmacol., 19, 335-341 (1997).
6. Qvist M. H., Hoeck U., Kreilgaard B., Madsen F., Frokjaer S., Eur. J. Pharm. Sci., 11, 59-68 (2000).
7. Sato K., Sugibayashi K., Morimoto Y., J. Pharm. Sci., 80, 104-107 (1991).
8. Schmook F. P., Meingassner J. G., Billich A., Int. J. Pharm., 215, 51-56 (2001).
9. Singh S., Zhao K., Singh J., Drug Chem. Toxicol., 25, 83-92 (2002).
10. Sowthwell D., Barry B. W., Woodford R., Int. J. Pharm., 18, 299-309 (1984).
11. Přǐborsky J., Mühlbachová E., J. Pharm. Pharmacol., 42, 468-472 (1990).
12. Sato K., Sugibayashi K., Morimoto Y., Omiya H., Enomoto N., J. Pharm. Pharmacol., 41, 379-383 (1989).
13. Yamaguchi K., Mitsui T., Aso Y., Sugibayashi K., J. Pharm. Sci., 97, 4391-4403 (2008).
14. Ngawhirunpat T., Panomsuk S., Opanasopit P., Rojanarata T., Hatanaka T., Pharmazie, 61, 331-335 (2006).
15. Schäfer-Koring M., Bock U., Diembeck W., Weimer M., Altern. Lab. Anim., 36, 161-187 (2008).
16. Takeuchi H., Terasaka S., Sakurai T., Furuya A., Urano H., Sugibayashi K., Exp. Anim. (in press).
17. Fujiwara A., Hinokitani T., Goto K., Lasers Med. Sci., 19, 210-217 (2005).
18. Koizumi A., Fujii M., Kondoh M., Watababe Y., Eur. J. Pharm. Biopharm., 57, 473-478 (2004).
19. Sekkat N., Kalia Y. N., Guy R. H., Pharm. Res., 21, 1390-1397 (2004).
20. Simonsen L., Fullerton A., Skin Pharmacol. Physiol., 20, 230-236 (2007).
21. Vallet V., Cruz C., Josse D., Bazire A., Lallement G., Boudry I., Toxicol. in Vitro, 21, 1182-1190 (2007).
22. Wang A., Seki T., Yuan D., Saso Y., Hosoya O., Chono S., Morimoto K., Biol. Pharm. Bull., 27, 1476-1479 (2004).
23. Dick I. P., Scott R. C., J. Pharm. Pharmacol., 44, 640-645 (1992).
24. Fang J. Y., Wu P. C., Huang Y. B., Tsai Y. H., Int. J. Pharm., 130, 121-135 (1996).
25. Hawkins G. S., Reifenrath W. G., Fundam. Appl. Toxicol., 4, S133-S144 (1984).
26. Monterio-Riviere N. A., Inman A. O., Riviere J. E. , Mcneill S. C., Francoeur M. L., Pharm. Res., 10, 1326-1331 (1993).
27. Roberts M. E., Mueller K. R., Pharm. Res., 7, 673-676 (1990).
28. Simon G. A., Maibach H. I., Skin Pharmacol. Appl. Skin Physiol., 13, 229-234 (2000).
29. Kurihara B. T., Woodworth M., Feisullin S., Beall P., Lab. Animal Sci., 36, 396-399 (1986).
30. Lavker R. M., Dong G., Zheng P., Murphy G. F., Am. J. Pathol., 138, 687-697 (1991).
31. Fujii M., Yamanouchi S., Hori N., Iwanaga N., Kawaguchi N., Matsumoto M., Biol. Pharm. Bull., 20, 249-254 (1997).
32. Franz T. J., J. Invest. Dermatol., 64, 190-195 (1975).
33. Hikima T., Yamada, K., Kimura T., Maibach H. I., Tojo K., Eur. J. Pharm. Biopharm., 54, 155-160 (2002).
34. Pinnagoda J., Tupker R. A., Agner T., Serup J., Contact Dermatitis, 22, 164-178 (1990).
35. Gabard B., Treffel P., Charton-Picard F., Eloy R., Current Probl. Dermatol., 23, 275-287 (1995).
36. Morimoto Y., Hatanaka T., Sugibayashi K., Omiya H., J. Pharm. Pharmacol., 44, 634-639 (1992).
37. Hatanaka T., Inuma M., Sugibayashi K., Morimoto Y., Chem. Pharm. Bull., 38, 3452-3459 (1990).
38. Watanabe T., Hasegawa T., Takahashi H., Ishibashi T., Takayama K., Sugibayashi K., Altern. Animal Test Experiment, 8, 1-14 (2001).
39. Netzlaff F., Schacfer U. F., Lehr C. M., Meiers P., Stahi J., Kietzmann M., Niedorf F., Altern. Lab. Anim., 34, 499-513 (2006).
40. Wertz P. W., Downing D. T., "Transdermal Drug Delivery," Marcel Dekker, New York, 1989, pp. 1-22.